By twisting the arm of the WHO to label Roundup a carcinogen, Monsanto will seek non-selective herbicide alternatives by way of Syngenta. The science-challenged goons thought they found a novel way to render GMOs useless, but instead Monsanto will continue to grow and dominate the AG industry as more and more farmers embrace its yield enhancing technology.
I can understand that possible new market entrants could cause some customer pause, but waiting until the end of 2016 and more likely 2017 is a long time to delay internal 3D development plans. I think the slow capital spending environment as evidenced by flat GDP growth is causing a slow-down that could pick up in the second half of this year.
This stock has endured a perfect storm of the HP ghost, two successive rounds of reduced guidance, and an industry slow-down amidst the weak capital spending environment. Management will have had ample time to prepare a positive presentation spin for next week's conference call...
Yes my mistake. $46 was his price target initiated last Oct 21st with the stock trading around $39. I still think the Oppenheimer analyst left a lot of money on the table. This is a multi-year growth story.
The stock opened up $1.50 until the broader market turned over. Some investors may be concerned about order sustainability, but this story is as good as ever. I am very pleased.
At over $43, the stock is discounting multi-year 15 -20% EPS growth according to my DCF model. This growth rate is very aggressive and surpasses even bullish sell-side expectations. I understand that some investors prescribe an above normal valuation to organic food companies, but barring a heroic take-out multiple (Annies)you are still dealing with a low margin suite of dairy product offerings. My target price is $30.
Sentiment: Strong Sell
No, the results were in-line as well as their revenue projection for the remainder of the year. Investors are impatient with product delays, but I look at this the same way I would view an emerging biotech company in its early stages to bring a product to market. Always takes longer than you think.
The management team is accustomed to working within the confines of a private Israel company (formerly Objet). While operating Objet, they did not have to deal with pesky investors and analysts who require constant hand holding and precise financial guidance. At this price, they could take the company private.
Yup, at first the headline on the tape looked favorable until the fine print says that the study does not warrant further study at this time
Somebody does not want you to know what I know...
Are you sitting at your command and control center stroking a white #$%$? Because you spied some very valuable insight for this board's readers and shagged slow eddie in the process. Nice job.
I suspect that the bag holders who bought at high price levels have already bailed leaving long-term strong hands and recent bargain hunters in the stock capped off with a handful of clueless retail trader types. Stock should stabilize from here.
This analyst was too clever by half. He was correct in enumerating all the negative industry fundamentals but missed the important element to successful security selection - intrinsic value. Too bad he lost so many of his clients so much money.